Syndax price target lowered to $16 from $18 at Scotiabank

Scotiabank lowered the firm’s price target on Syndax (SNDX) to $16 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock based on its revised market share estimates for ziftomenib in relapsed/refractory KMT2Ar acute lymphoblastic leukemia and front-line acute leukemia treatment settings, the analyst tells investors.